Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6466 to 6480 of 8929 results

  1. LiverMultiScan for liver disease (MIB181)

    This advice has been updated and replaced by NICE healthtech guidance 655.

    Withdrawn advice

  2. SEM Scanner for pressure ulcer prevention (MIB182)

    This advice has been updated and replaced by NICE medical technologies guidance 51.

    Withdrawn advice

  3. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection.

    Withdrawn advice

  4. Danis stent for acute oesophageal variceal bleeds (MIB185)

    This advice has been updated and replaced by NICE healthtech guidance 574.

    Withdrawn advice

  5. Endo-SPONGE for colorectal anastomotic leakage (MIB188)

    This advice has been updated and replaced by NICE healthtech guidance 605.

    Withdrawn advice

  6. The V.A.C. Veraflo Therapy system for infected wounds (MIB189)

    This advice has been updated and replaced by NICE healthtech guidance 566.

    Withdrawn advice

  7. UroShield for preventing catheter-associated urinary tract infections (MIB191)

    This advice has been updated and replaced by NICE healthtech guidance 620.

    Withdrawn advice

  8. Guidance on the use of inhaler systems (devices) in children under the age of 5 years with chronic asthma (TA10)

    This guidance has been updated and replaced by the NICE guideline on asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN).

    Withdrawn guidance

  9. Parent-training/education programmes in the management of children with conduct disorders (TA102)

    This guidance has been updated and replaced by NICE guideline CG158.

    Withdrawn guidance

  10. Abatacept for the treatment of rheumatoid arthritis (TA141)

    This appraisal has been updated and replaced by NICE technology appraisal guidance 195.

    Withdrawn guidance

  11. Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)

    This guidance has been replaced by NICE technology appraisal guidance 323.

    Withdrawn guidance

  12. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.

    Withdrawn guidance

  13. Rimonabant for the treatment of overweight and obese adults (TA144)

    This appraisal has been withdrawn. This is because the marketing authorisation for rimonabant was withdrawn on 16 January 2009.

    Withdrawn guidance

  14. Bevacizumab for the first-line treatment of metastatic breast cancer (TA147)

    This appraisal has been updated and replaced by NICE technology appraisal 214.

    Withdrawn guidance

  15. Zanamivir for the treatment of influenza in adults (TA15)

    This guidance has been replaced by NICE technology appraisal guidance 58 [Replaced by NICE technology appraisal guidance 168].

    Withdrawn guidance